✦ LIBER ✦

5-HT radioligands for human brain imaging with PET and SPECT

✍ Scribed by Louise M. Paterson; Birgitte R. Kornum; David J. Nutt; Victor W. Pike; Gitte M. Knudsen

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 523 KB
Volume: 33
Category: Article
ISSN: 0198-6325
DOI: 10.1002/med.20245

No coin nor oath required. For personal study only.

✦ Synopsis

The serotonergic system plays a key modulatory role in the brain and is the target for many drug treatments for brain disorders either through reuptake blockade or via interactions at the 14 subtypes of 5-HT receptors. This review provides the history and current status of radioligands used for positron emission tomography (PET) and single photon emission computerized tomography (SPECT) imaging of human brain serotonin (5-HT) receptors, the 5-HT transporter (SERT), and 5-HT synthesis rate. Currently available radioligands for in vivo brain imaging of the 5-HT system in humans include antagonists for the 5-HT(1A), 5-HT(1B), 5-HT(2A), and 5-HT(4) receptors, and for SERT. Here we describe the evolution of these radioligands, along with the attempts made to develop radioligands for additional serotonergic targets. We describe the properties needed for a radioligand to become successful and the main caveats. The success of a PET or SPECT radioligand can ultimately be assessed by its frequency of use, its utility in humans, and the number of research sites using it relative to its invention date, and so these aspects are also covered. In conclusion, the development of PET and SPECT radioligands to image serotonergic targets is of high interest, and successful evaluation in humans is leading to invaluable insight into normal and abnormal brain function, emphasizing the need for continued development of both SPECT and PET radioligands for human brain imaging.

📜 SIMILAR VOLUMES

p-[18F]-MPPF: A potential radioligand fo

p-[18F]-MPPF: A potential radioligand for PET studies of 5-HT1A receptors in humans

✍ Chyng-Yann Shiue; Grace G. Shiue; P. David Mozley; Mei-Ping Kung; Zhi-Ping Zhuan 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

The purpose of this study was to develop a radiopharmaceutical that could be used to selectively image 5-HT 1A receptors with positron emission tomography (PET). No-carrier-added 4-(28-methoxyphenyl)-1-[28-(N-29-pyridinyl)-p-[ 18 F]fluorobenzamido]ethylpiperazine ( p-[ 18 F]-MPPF, 2) was synthesized

BZM055, an Iodinated Radiotracer Candida

BZM055, an Iodinated Radiotracer Candidate for PET and SPECT Imaging of Myelin and FTY720 Brain Distribution

✍ Dr. Emmanuelle Briard; Dr. David Orain; Dr. Christian Beerli; Dr. Andreas Billic 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 452 KB

## Abstract FTY720 (fingolimod, Gilenya®) is a sphingosine 1‐phosphate (S1P) receptor modulator that shows significant therapeutic efficacy after oral administration to patients of multiple sclerosis. Because FTY720 does not contain any atom whose PET or SPECT radioisotope would have a half‐life co

Altropane, a SPECT or PET imaging probe

Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain

✍ Bertha K. Madras; Lawrence M. Gracz; Michele A. Fahey; David Elmaleh; Peter C. M 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 362 KB 👁 2 views

Increasing evidence suggests that the dopamine transporter is situated almost exclusively on dopamine neurons. Accordingly, it is an valuable marker for Parkinson's disease and other pathological states of dopamine neurons. We previously demonstrated that the potent dopamine transport inhibitor [ 12

Automated radiosynthesis of [18F]SPA-RQ

Automated radiosynthesis of [18F]SPA-RQ for imaging human brain NK1 receptors with PET

✍ Frederick T. Chin; Cheryl L. Morse; H. Umesha Shetty; Victor W. Pike 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 316 KB

## Abstract [^18^F]SPA‐RQ is an effective radioligand for imaging brain neurokinin type‐1 (NK~1~) receptors in clinical research and drug discovery with positron emission tomography. For the automated regular production of [^18^F]SPA‐RQ for clinical use in the USA under an IND we chose to use a mod

Synthesis and PET evaluation of (R)-[S-m

Synthesis and PET evaluation of (R)-[S-methyl-11C]thionisoxetine, a candidate radioligand for imaging brain norepinephrine transporters

✍ Magnus Schou; Victor W. Pike; Andrea Varrone; Balázs Gulyás; Lars Farde; Christe 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 164 KB

## Abstract __Introduction:__ (__R__)‐3‐(2‐(methylthio)phenoxy)‐__N__‐methyl‐3‐phenylpropan‐1‐amine [(__R__)–thionisoxetine; **1**] is a potent inhibitor of the norepinephrine transporter (NET). We aimed to label **1** with carbon‐11 (__t__~1/2~ = 20.4 min) for evaluation as a radioligand for imagi

Altropane, a SPECT or PET imaging probe

Altropane, a SPECT or PET imaging probe for dopamine neurons: I. dopamine transporter binding in primate brain

✍ Bertha K. Madras; Peter C. Meltzer; Anna Y. Liang; David R. Elmaleh; John Babich 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB 👁 2 views

Increasing evidence suggests that the dopamine transporter is an important marker for physiological and pathological changes in dopamine neurons. Potent dopamine transport inhibitors of the phenyltropane series (e.g., WIN 35,428 or CFT) are particularly suitable for PET (positron emission tomography